Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A fixed-dose combination of oxymetazoline (a sympathomimetic decongestant) and fluticasone (a corticosteroid) used primarily for the treatment of allergic rhinitis, particularly for patients with moderate-to-severe nasal congestion. This combination leverages the complementary mechanisms of both medications, providing rapid relief from congestion through oxymetazoline's vasoconstriction of nasal blood vessels and sustained anti-inflammatory benefits through fluticasone's inhibition of inflammatory mediators. Clinical studies have shown this combination to be superior to fluticasone alone in relieving nasal congestion and that the corticosteroid component helps prevent the rebound congestion or rhinitis medicamentosa typically associated with long-term oxymetazoline use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxymetazoline + fluticasone.